AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
Dosage
150-500 mg subcutaneous or IV daily (extremely expensive)
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration

Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Exercise Mimetic
44% endurance improvement in mice without any exercise training.
AMPK Activation
Pharmacologically activates the cell's master energy sensor.
Mechanism of Action
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a nucleoside analogue that, upon cellular uptake, is phosphorylated by adenosine kinase to ZMP (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 5'-monophosphate). ZMP is structurally analogous to AMP and mimics its binding to the gamma regulatory subunit of AMP-activated protein kinase (AMPK), allosterically activating the kinase without requiring actual energy depletion or ATP consumption.
AMPK is the cell's master energy sensor and metabolic regulator. Under normal conditions, AMPK is activated when the AMP/ATP ratio rises during energy stress (exercise, fasting, hypoxia). By pharmacologically activating AMPK independently of energy status, AICAR triggers the same metabolic adaptations that exercise produces. AMPK phosphorylates and inhibits acetyl-CoA carboxylase (ACC), relieving the inhibition of carnitine palmitoyltransferase I (CPT-1) and dramatically increasing mitochondrial fatty acid oxidation. It stimulates glucose uptake by promoting GLUT4 translocation to the cell membrane, independent of insulin signaling. It activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis, increasing mitochondrial number and function.
The exercise-mimetic effects extend to muscle fiber type transformation. AMPK/PGC-1α activation shifts gene expression toward slow-twitch (type I) oxidative fiber characteristics, increasing fatigue resistance and endurance capacity. In mouse studies, AICAR treatment for 4 weeks improved running endurance by 44% without any actual exercise training — a finding that generated enormous interest (and controversy) when published. AICAR also activates SIRT1 through increased NAD+ availability (due to enhanced fatty acid oxidation), connecting to the same longevity-associated sirtuin pathway targeted by NAD+ supplementation. However, practical use in humans is limited by the very high doses required (hundreds of milligrams to grams), poor oral bioavailability, and the extreme cost of pharmaceutical-grade AICAR. It was banned by WADA in 2011 as a metabolic modulator.
Regulatory Status
Not FDA approved. Research reagent. Banned by WADA (metabolic modulator category). Used clinically in cardiac surgery (adenosine pathway) but not for performance.
Risks & Safety
Common
diarrhea, injection site pain, flushing, mild fatigue.
Serious
lactic acidosis at high doses (shifts metabolism toward anaerobic pathways), potential heart effects, low blood sugar.
Rare
severe metabolic acidosis, heart rhythm problems. Very expensive ($1000+ per treatment cycle). Limited human safety data at performance-enhancing doses.
Compare AICAR With
Research Papers
30Published: February 4, 2026
AI Summary
AICAR protected kidneys from ischemia-reperfusion injury by dampening harmful inflammation and restoring energy metabolism. The drug works through two linked mechanisms—blocking inflammatory cell death and repairing cellular fuel pathways—which could support new treatments for acute kidney injury.
Published: November 17, 2025
AI Summary
AICAR reduced insulin-driven glucose uptake in fat cells by blocking sugar transporters, but this effect did not depend on AMPK. Instead, it required AICAR’s conversion to ZMP, revealing a separate mechanism that could affect how fat cells handle glucose.
Published: September 26, 2025
AI Summary
Researchers explored how aerobic exercise might protect the diabetic heart by affecting inflammation pathways. The abstract introduces the topic; full results would clarify the role of P2X4 and inflammasome signaling.
Published: September 25, 2025
AI Summary
Raising CD137L levels in melanoma tumors strengthened T cell responses and improved outcomes with immune checkpoint drugs. AICAR boosted CD137L and worked together with PD-1 or CTLA-4 blockade, suggesting a new combination strategy for melanoma.
Published: December 21, 2025
AI Summary
AMPK links the hunger hormone leptin to electrical activity in memory-forming brain cells by controlling a key ion channel. Activating AMPK with AICAR reduced channel activity and reversed leptin’s effect, showing how metabolism can shape brain signaling.
Published: July 8, 2025
AI Summary
Cisplatin lowered levels of irisin, a muscle-derived factor that supports brain health, in mice and muscle cells. AICAR partly reversed this effect, suggesting a pathway that could explain cancer treatment–related muscle loss and cognitive decline.
Published: June 30, 2025
AI Summary
A new peptide was found that activates AMPK by blocking an inhibitory phosphorylation site, which AICAR itself triggers as feedback. Blocking that site reduced sugar production in liver cells and promoted mitochondrial division, pointing to a new way to target AMPK.
Published: July 29, 2025
AI Summary
Mice lacking both AXIN1 and AXIN2 in muscle still showed normal AMPK and mTOR signaling and glucose uptake in response to AICAR, insulin, and contraction. The results challenge the idea that AXIN proteins are required for these pathways in muscle.
Published: June 1, 2025
AI Summary
The gut hormone neurotensin suppresses AMPK and raises fat uptake in intestinal cells, worsening obesity and aging effects. Mice lacking neurotensin lived longer on a high-fat diet, and AICAR or metformin countered neurotensin by boosting AMPK and lowering fat uptake.
Published: April 23, 2025
AI Summary
A variant in the ATIC gene, which is involved in AICAR metabolism, was linked to a higher chance of methotrexate not working in rheumatoid arthritis. The finding supports the role of adenosine-related pathways in how methotrexate controls inflammation.
Published: June 2, 2025
AI Summary
A review links early RNA chemistry to modern metabolism, including how purine damage could have produced AICAR-like compounds. The work suggests key biosynthetic pathways may have arisen from RNA and nucleotide damage in prebiotic conditions.
Published: March 31, 2025
AI Summary
Activating AMPK in the brain with AICAR reduced leaky gut in rats by way of orexin and the vagus nerve; injecting AICAR into the body had no effect. The findings suggest brain AMPK helps maintain intestinal barrier function and could be relevant for leaky gut–related conditions.
Published: June 17, 2025
AI Summary
AMPK activation with AICAR or metformin phosphorylated a key blood vessel channel, improving vessel relaxation and reducing early hypertension in mice given angiotensin II. The results point to AMPK as a pathway for treating blood vessel dysfunction.
Published: April 4, 2025
AI Summary
Aging-related loss of NAD kinase in insulin-producing cells raised AICAR and AMPK activity, which reduced insulin release in response to glucose. Blocking AMPK or adding folate restored insulin secretion, suggesting new targets for age-related diabetes.
Published: June 22, 2025
AI Summary
Researchers examined how AMPK and mTOR signaling influence cell growth and type changes in pterygium fibroblasts. The abstract describes the study aim; full results would clarify whether these pathways could be targeted for treatment.
Published: February 20, 2025
AI Summary
AICAR reduced inflammatory pain in mice by dampening STAT3 signaling in immune cells, lowering oxidative stress and mitochondrial damage. The findings suggest AMPK activation could be a useful strategy for managing inflammatory pain.
Published: November 17, 2024
AI Summary
Chronic stress reduced AICAR and related molecules in young rats and impaired memory. Giving AICAR restored those metabolites and synaptic markers and improved memory, pointing to a metabolic pathway that could be targeted for stress-related cognitive problems.
Published: November 19, 2024
AI Summary
A mitochondrial stressor triggered liver fibrosis by disrupting mitochondria and lysosomes in stellate cells. AICAR reversed this activation, suggesting AMPK-related pathways could be targeted to slow or prevent liver fibrosis.
Published: November 14, 2024
AI Summary
Several adenosine-like compounds activated cellular cleanup (autophagy) more strongly than AICAR, partly through AMPK. Some effects persisted without AMPK, suggesting other targets. The work points to new autophagy activators for metabolic and neurodegenerative diseases.
Published: December 9, 2024
AI Summary
The plant compound morin triggered cell death and autophagy in prostate cancer cells by activating AMPK and ULK1 and suppressing mTOR. AICAR strengthened these effects, suggesting AMPK activation could enhance morin’s anticancer activity.
Published: October 25, 2024
AI Summary
Researchers explored whether aerobic exercise improves muscle stem cell function and repair in aged mice. The abstract states the study focus; full results would clarify how exercise affects senescent stem cells and regeneration.
Published: July 15, 2024
AI Summary
Researchers investigated how resistance exercise reduces heart scarring after a heart attack, focusing on irisin and AMPK-Sirt1 signaling. The abstract describes the study aim; full results would clarify the role of irisin in these benefits.
Published: May 7, 2024
AI Summary
Researchers tested whether simvastatin reduces silica-induced lung inflammation and scarring in rats, focusing on AMPK and NOX pathways. The abstract describes the study aim; full results would clarify the mechanism and potential for treating lung fibrosis.
Published: August 3, 2024
AI Summary
AMPK activation with AICAR slowed sperm-supporting cell growth and mitochondrial function in boar testis cells, while blocking AMPK had the opposite effect. The work suggests AMPK helps control sperm cell development and could inform treatments for male infertility.
Published: August 25, 2024
AI Summary
Researchers examined whether AMPK influences IL-36–driven skin inflammation in pustular psoriasis. The abstract describes the study aim; full results would clarify if AMPK activation could offer a more affordable treatment option.
Published: May 18, 2024
AI Summary
Diabetes-related vesicles carrying miR-130b-3p worsened joint cartilage damage by suppressing AMPK and mitochondrial function. AICAR reversed these effects, suggesting AMPK activation could help protect joints in people with diabetes.
Published: March 7, 2024
AI Summary
Researchers explored whether AMPK activation reduces chronic migraine–related sensitization by shifting brain immune cells toward an anti-inflammatory state. The abstract describes the study aim; full results would clarify the mechanism and therapeutic potential.
Published: April 4, 2024
AI Summary
Oleic acid promoted fat buildup and inflammation in oil glands of the eyelid, contributing to dry eye–related gland dysfunction. AICAR reversed these effects by restoring AMPK signaling, suggesting AMPK activation could help treat this condition.
Published: July 4, 2024
AI Summary
Researchers tested whether AICAR in the brain lowers blood pressure by activating AMPK and Nrf2 in a key blood-pressure control region. The abstract describes the hypothesis; full results would clarify whether this pathway could be targeted for hypertension.
Published: January 24, 2024
AI Summary
Researchers investigated whether aerobic exercise protects the heart after a heart attack by affecting miR-133a-3p and connective tissue growth factor. The abstract describes the study aim; full results would clarify the mechanism.
Frequently Asked Questions
What is AICAR?
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
What is AICAR used for?
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
What is the dosage for AICAR?
Research: 150-500 mg subcutaneous or IV once daily. Extremely expensive due to high dosing requirements (milligram quantities needed). Often cycled 4-8 weeks.
What are the side effects of AICAR?
Common: diarrhea, injection site pain, flushing, mild fatigue. Serious: lactic acidosis at high doses (shifts metabolism toward anaerobic pathways), potential heart effects, low blood sugar. Rare: severe metabolic acidosis, heart rhythm problems. Very expensive ($1000+ per treatment cycle). Limited human safety data at performance-enhancing doses.
How does AICAR work?
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a nucleoside analogue that, upon cellular uptake, is phosphorylated by adenosine kinase to ZMP (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 5'-monophosphate). ZMP is structurally analogous to AMP and mimics its binding to the gamma regulatory subunit of AMP-activated protein kinase (AMPK), allosterically activating the kinase without requiring actual energy depletion or ATP consumption. AMPK is the cell's master energy sensor and metabolic regulator. Under normal conditions, AMPK is activated when the AMP/ATP ratio rises during energy stress (exercise, fasting, hypoxia). By pharmacologically activating AMPK independently of energy status, AICAR triggers the same metabolic adaptations that exercise produces. AMPK phosphorylates and inhibits acetyl-CoA carboxylase (ACC), relieving the inhibition of carnitine palmitoyltransferase I (CPT-1) and dramatically increasing mitochondrial fatty acid oxidation. It stimulates glucose uptake by promoting GLUT4 translocation to the cell membrane, independent of insulin signaling. It activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis, increasing mitochondrial number and function. The exercise-mimetic effects extend to muscle fiber type transformation. AMPK/PGC-1α activation shifts gene expression toward slow-twitch (type I) oxidative fiber characteristics, increasing fatigue resistance and endurance capacity. In mouse studies, AICAR treatment for 4 weeks improved running endurance by 44% without any actual exercise training — a finding that generated enormous interest (and controversy) when published. AICAR also activates SIRT1 through increased NAD+ availability (due to enhanced fatty acid oxidation), connecting to the same longevity-associated sirtuin pathway targeted by NAD+ supplementation. However, practical use in humans is limited by the very high doses required (hundreds of milligrams to grams), poor oral bioavailability, and the extreme cost of pharmaceutical-grade AICAR. It was banned by WADA in 2011 as a metabolic modulator.
How is AICAR administered?
AICAR is administered via subcutaneous or intravenous injection.
What is the half-life of AICAR?
The half-life of AICAR is 2-3 hours.
Is AICAR legal?
Not FDA approved. Research reagent. Banned by WADA (metabolic modulator category). Used clinically in cardiac surgery (adenosine pathway) but not for performance.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
ACE-031
An experimental drug that acts as a 'decoy' to intercept myostatin and other muscle-limiting signals before they reach your muscles. It produced rapid muscle gains in clinical trials without any exercise. However, development was halted because it also accidentally blocked signals needed to maintain healthy blood vessels, causing nosebleeds and visible broken blood vessels. A powerful proof-of-concept that myostatin blocking works, but too dangerous in its current form.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.
BPC-157 + TB-500
A two-in-one product that pairs BPC-157 and TB-500 to target different healing pathways. BPC-157 focuses on gut, tendon, and ligament repair by supporting blood vessel growth and nitric oxide signaling, while TB-500 helps cells move to injury sites for body-wide tissue repair. The most popular peptide combination for healing and recovery.